{"id":464867,"date":"2021-03-25T07:03:10","date_gmt":"2021-03-25T11:03:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464867"},"modified":"2021-03-25T07:03:10","modified_gmt":"2021-03-25T11:03:10","slug":"medicenna-announces-preclinical-data-on-mdna11-with-anti-pd-1-therapy-and-unveils-novel-bifunctional-superkines-at-the-cytokine-based-cancer-immunotherapies-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-preclinical-data-on-mdna11-with-anti-pd-1-therapy-and-unveils-novel-bifunctional-superkines-at-the-cytokine-based-cancer-immunotherapies-summit\/","title":{"rendered":"Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit"},"content":{"rendered":"
\n

\n — MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model<\/em>
\n \n <\/p>\n

\n — Preclinical data demonstrates the potential of BiSKITs<\/em>
\n
\n TM<\/em>
\n <\/sup>
\n (<\/em>
\n
\n Bi<\/em>
\n <\/strong>
\n -functional <\/em>
\n
\n S<\/em>
\n <\/strong>
\n uper<\/em>
\n
\n K<\/em>
\n <\/strong>
\n ine <\/em>
\n
\n I<\/em>
\n <\/strong>
\n mmuno<\/em>
\n
\n T<\/em>
\n <\/strong>
\n herapie<\/em>
\n
\n s<\/em>
\n <\/strong>
\n ) to effectively target immunologically \u201ccold\u201d tumors <\/em>\n <\/p>\n

TORONTO and HOUSTON, March 25, 2021 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced an upcoming oral presentation of preclinical data on the Company\u2019s Superkine platform programs. The presentation will take place today, March 25, 2021 at 2:25 pm ET at the virtual Cytokine-Based Cancer Immunotherapies Summit.<\/p>\n

The presentation will feature preclinical data on MDNA11, a long-acting IL-2 Superkine that preferentially binds the IL-2 beta receptor (IL-2R\u03b2) on immune cells, as well as an overview of Medicenna\u2019s Bi<\/strong>-functional S<\/strong>uperK<\/strong>ine I<\/strong>mmunoT<\/strong>herapies<\/strong> (BiSKITsTM<\/sup>) program, which includes engineered interleukins designed to target immunologically \u201ccold\u201d tumors.<\/p>\n

\u201cImmunosuppressive tumor microenvironments (TMEs) often limit the efficacy of checkpoint inhibitors, highlighting an unmet need for new therapeutic agents that can induce an anti-cancer immune response and overcome immunotherapy resistance mechanisms,\u201d said Fahar Merchant, PhD, President and CEO of Medicenna. \u201cNew data show that MDNA11 monotherapy or when combined with anti-PD-1 therapy stimulated potent immune responses in preclinical tumor models highlighting the potential of our Superkine platform to address this need. This capability is further highlighted by results related to our BiSKITsTM<\/sup> program, which demonstrates the ability of an IL-13 super-antagonist to suppress the TME known to promote cancer growth. By linking the IL-13 super-antagonist with an IL-2 super-agonist via a protein scaffold, we have generated a novel long acting dual specific cytokine designed to simultaneously activate anti-cancer immune cells while mitigating the immunosuppressive effects of the TME. We plan to present additional data on our IL-2\/IL-13 dual specific cytokine next month, which may further validate the versatility of our Superkine platform.\u201d<\/p>\n

The oral presentation, titled \u201cDesigner Cytokines\u201d<\/em> will be given by Dr. Merchant today, March 25, 2021 at 2:25 pm ET. Dr. Merchant will also participate in a live Q&A session at 3:05 pm ET today. Those interested in viewing the live presentation or participating in the Q&A session can register for the Cytokine-Based Cancer Immunotherapies Summit here<\/a>.<\/p>\n

Highlights from the presentation include:<\/p>\n